Navigation Links
Catalent Announces Appointment of Sally Langa as New Vice President of Development and Analytical Services
Date:1/21/2016

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced the appointment of Sally Langa to the position of Vice President, Business Development, for Catalent’s Development and Analytical Services offerings. In this role, Ms. Langa will be responsible for growing Catalent’s early phase development business for small molecule compounds, including analytical services, formulation development, and micronization.

Ms. Langa joins Catalent from Halo Pharma where she held the role of Vice President, Sales and Marketing. Her career within the pharmaceutical services industry, which spans almost thirty years, has also seen her hold a number of senior positions at Patheon.

“Sally brings a huge amount of experience to Catalent and will be a pivotal part of the team charged with meeting the company’s ambitious growth targets,” commented Jonathan Arnold, Vice President and General Manager of Advanced Delivery Technologies. “Catalent sees great growth potential in its early stage development activities, as well as continued opportunity to integrate these services further into the clinical and commercial phases of development.”

Ms. Langa is an active member of the Drug, Chemical and Associated Technologies (DCAT) Association, and is currently on the Technology Committee. She is also a Trustee on the Board of the Pharma & Biopharma Outsourcing Association (PBOA).

Catalent’s Development and Analytical services, located at sites throughout the US and Europe, offer global solutions with specialty handling capabilities for controlled substances, highly potent, cytotoxic, and temperature critical compounds, to handle the most challenging molecules.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2016/01/prweb13175195.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
2. Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal
3. Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems
4. Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market
5. Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference
6. Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions
7. Catalent Announces Two Senior Appointments to its Biologics Business
8. Bioavailability and Controlled Release Symposium Announced by Catalent Applied Drug Delivery Institute
9. Best Practice and Strategies in Risk Mitigation to be Presented by Catalent Expert at Internal Audit Summit
10. New OptiPact™ Technology Introduced by Catalent
11. Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
(Date:8/14/2019)... ... August 14, 2019 , ... ... Team Assistant support, has earned a place on the Inc. magazine 500/5000 list ... inclusion marks nearly a decade of ScribeAmerica’s recognition as one of the fastest ...
(Date:8/14/2019)... ... August 13, 2019 , ... New Hampshire-based Vera Roasting Company , makers ... expansion of its line of CBD-infused coffees with the release of a new higher-dosage ... bag. , “We are excited to expand our CBD-infused product lines to include ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... In a ... the purpose of doubt in your belief systems. , “Doubt can obliterate your old ... on the path to examining them to expand your understanding and your awareness. Trust ...
(Date:8/14/2019)... ... August 14, 2019 , ... While it is commonly ... their food and beverage choices can help them manage and, in some cases, reverse ... finds that about a quarter of U.S. adults are trying to manage a health ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the ... are around 150 million people worldwide that are affected by treatment-resistant hypertension, resulting ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... since 2005, announced it has successfully completed enrollment of 690 patients for a ... a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial ...
(Date:8/14/2019)... ... August 14, 2019 , ... Bach Pharma, Inc., a ... its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative ... data from multiple animal studies have proven that GVT has the potential to ...
Breaking Medicine Technology: